47
47M.F MedMira Inc
- Market cap
- EUR 20.7M
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Apr 2026.
Is 47M.F undervalued?
Graham numberThe Graham number of MedMira Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
MedMira Inc fundamental analysis
No fundamental analysis for MedMira Inc yet.
MedMira Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About MedMira Inc
MedMira Inc., a biotechnology company, researches, develops, manufactures, and sells rapid diagnostics and technology platforms in North America, Europe, and internationally. The company offers Reveal HIV, a test that detects antibodies to HIV-1 and HIV-2 in whole blood, serum, or plasma; Reveal TP, a rapid syphilis antibody test that detects treponema pallidum antibodies in serum, plasma, or whole blood; Multiplo, a line of multiplex tests for HIV-1/2, Hepatitis B and C, an…
Full company profileMedMira Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Apr 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
MedMira Inc annual financial statements (CAD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 2.26M | 747K | 589K | 527K | 919K | 2.14M | 952K | 433K | 413K | 241K | 427K |
| Gross Profit | 1.02M | 478K | 461K | 423K | 572K | 1.72M | 304K | 300K | 226K | 173K | 316K |
| Operating Income | -4.48M | -2.13M | -1.84M | -1.30M | -1.30M | 5.90K | -1.27M | -1.78M | -2.43M | -3.45M | -1.68M |
| EBITDA | - | -2.11M | -1.75M | -1.28M | -1.13M | 185K | -1.07M | -1.58M | -2.13M | -3.13M | -1.38M |
| Net Income | -5.16M | -2.66M | -2.51M | -2.11M | -2.05M | -676K | -1.83M | -2.68M | -3.33M | -4.52M | -2.61M |
| EPS | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 |
| Balance Sheet | |||||||||||
| Total Assets | 870K | 674K | 301K | 253K | 3.40M | 3.89M | 3.83M | 3.65M | 6.07M | 3.68M | 3.40M |
| Total Liabilities | 8.53M | 9.66M | 11.7M | 13.8M | 19.0M | 19.6M | 16.2M | 18.7M | 24.1M | 26.2M | 27.9M |
| Shareholders' Equity | -7.66M | -8.98M | -11.4M | -13.5M | -15.6M | -15.7M | -12.4M | -15.0M | -18.0M | -22.6M | -24.5M |
| Cash & Short-term Investments | 46.1K | 156K | 0.00 | 88.9K | 402K | 0.00 | 33.5K | 13.2K | 2.10M | 14.9K | 0.00 |
| Cash Flow | |||||||||||
| Operating Cash Flow | -4.09M | -1.89M | -795K | -941K | -316K | -505K | -1.88M | -1.27M | -2.94M | -3.15M | -898K |
| Capital Expenditure | 27.2K | 3.34K | 3.34K | 102K | 102K | 36.5K | 69.7K | 1.27K | 743K | 7.47K | 0.00 |
| Free Cash Flow | - | -1.89M | -795K | -941K | -316K | -505K | -1.95M | -1.27M | -3.68M | -3.15M | -898K |
| Ratios | |||||||||||
| ROA | -593.0% | -395.0% | -834.0% | -834.2% | -60.2% | -17.4% | -47.8% | -73.3% | -54.8% | -122.9% | -76.6% |
| Net Profit Margin | -228.6% | -356.1% | -426.1% | -399.4% | -222.5% | -31.5% | -192.4% | -618.6% | -806.2% | -1,881.2% | -610.9% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
MedMira Inc dividends
MedMira Inc has not paid dividends in the last 9 fiscal years.
Who owns MedMira Inc
- Insiders 65.54%
- Institutions 0.00%
- Public & others 34.46%
- Shares outstanding 702M
- Free float 210M
MedMira Inc company profile
- Company name
- MedMira Inc
- Ticker
- 47M.F
- ISIN
- CA58501R1029
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- July
- Address
- 155 Chain Lake Drive, Halifax, NS, Canada, B3S 1B3
- Phone
- 902 450 1588
- Website
- medmira.com
About MedMira Inc
MedMira Inc., a biotechnology company, researches, develops, manufactures, and sells rapid diagnostics and technology platforms in North America, Europe, and internationally. The company offers Reveal HIV, a test that detects antibodies to HIV-1 and HIV-2 in whole blood, serum, or plasma; Reveal TP, a rapid syphilis antibody test that detects treponema pallidum antibodies in serum, plasma, or whole blood; Multiplo, a line of multiplex tests for HIV-1/2, Hepatitis B and C, and syphilis; and Miriad triple product for preliminary screening of HIV and hepatitis. It also provides the Miriad RVF toolkit, which facilitates the development and commercialization of rapid diagnostics; and Reveal G4 HIV tests. The company was founded in 1993 and is headquartered in Halifax, Canada. MedMira Inc. is a subsidiary of MedMira Holding AG.
MedMira Inc management
4- Mr. Hermes ChanCo-Founder, CEO, President & Director
- Mr. Markus M. MeileChief Financial Officer
- Dr. Sam RatnamDirector of Scientific & Regulatory Affairs
- Stewart McKelveyLegal Counsel